Clinuvel’s Phototoxicity Drug Scenesse Approved In Third Market
Product Also To Be Studied In Ischemic Stroke
Executive Summary
Australian patients with phototoxicity due to the rare condition EPP will now have their first treatment option – provided the drug's developer, Clinuvel, secures reimbursement under the Pharmaceutical Benefits Scheme.